400 POSTER Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer

✍ Scribed by L.S. Rosen; M.S. Gordon; H.I. Hurwitz; D.S. Mendelson; D. Kleinzweig; B.J. Adams; C.P. Theuer

• Book ID: 119599556
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 58 KB
• Volume: 6
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(08)72334-6